Peptide-Detectable Agent Conjugates for Beta Cell Mass Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for measuring beta cell mass in diabetes are unreliable and lack non-invasive imaging tools, hindering early diagnosis, monitoring of therapeutic efficacy, and discovery of new therapies.
Innovation Solution
Development of peptide-detectable agent conjugates that specifically bind to the glucagon-like peptide-1 receptor (GLP-1R) for imaging beta cell mass using near-infrared (NIR), single photon emission computed tomography (SPECT), positron emission tomography (PET), or magnetic resonance imaging (MRI), incorporating fluorophores like VT-680 or VT-750 and unnatural amino acids for high specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serum tests such as insulin/C-peptide are used to measure beta cell mass, then the measurement process is simple and non-invasive, but the reliability and accuracy of beta cell mass measurement is poor
Solution Approach 1:
The patent uses GLP-1R targeting peptides as intermediary agents that specifically bind to beta cell receptors. These peptides serve as mediators between the imaging system and beta cells, enabling indirect but accurate visualization of beta cell mass without requiring direct measurement or complex surgical procedures.
Solution Approach 2:
The patent employs detectable agents with specific optical or nuclear parameters (fluorescence emission, positron emission, SPECT signal) that can be detected by imaging modalities. By changing the detection parameter from simple serum chemistry to targeted molecular imaging signals, the reliability of beta cell mass measurement is significantly improved.
2Reliability
If autopsy is used as the gold standard for measuring beta cell mass, then the measurement accuracy is high, but the method is invasive and cannot be used for living subjects or longitudinal monitoring
Solution Approach 1:
The patent replaces the mechanical/surgical approach of autopsy with a non-invasive molecular imaging system. Instead of physically removing and examining tissue, the invention uses detectable agents that bind to beta cells and are visualized through imaging modalities such as PET, SPECT, or fluorescence imaging, thereby maintaining accuracy while eliminating invasiveness.
Solution Approach 2:
The GLP-1R targeting peptide acts as an intermediary that allows indirect observation of beta cells in living subjects. This mediator enables the imaging system to 'see' beta cells through their receptor expression without requiring direct physical access or tissue removal.
3Measurement precision
If current imaging modalities are used without beta cell-specific targeting, then the imaging system is simple and widely available, but the specificity for beta cell detection is insufficient
Solution Approach 1:
The patent creates composite conjugates by combining GLP-1R targeting peptides with detectable agents. This composite structure integrates the specific binding capability of the peptide with the detectability of the agent, achieving both high specificity for beta cells and detectability through standard imaging modalities.
Solution Approach 2:
The detectable agent is specifically localized to beta cells through the targeting peptide. This local quality ensures that the imaging signal originates specifically from beta cell locations rather than diffuse background, thereby achieving high measurement precision and specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables sensitive and specific imaging of beta cell mass, facilitating early detection of diabetes, monitoring of treatments, and discovery of new therapies by providing a non-invasive means to quantify beta cell changes.
Implementation Method 1
In some embodiments, the fluorophore is VT-680 or VT-750
Implementation Method 2
positron emission tomography (PET) scan
Implementation Method 3
single photon emission computed tomography (SPECT) scan
Implementation Method 4
magnetic resonance imaging (MRI) scan
Data Source
AI summary
The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.